Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 272 |
| Active Pipeline (Recruiting Now) | 132 (69) |
| Completed vs Stopped Early | 88 / 52 (19.1%) |
| Median Closed Actual Enrollment | 160 participants |
| Physical Hospital Site Disclosure | 97.3% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 78 (14 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Hospital Universitario 12 de Octubre | Madrid | 24 |
| Asan Medical Center | Seoul | 21 |
| Hospital Universitari Vall d'Hebron | Barcelona | 19 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06615479 | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lena | Phase III | RECRUITING |
| NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients Wit | Phase II/III | RECRUITING |
| NCT06869551 | A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic | Phase III | RECRUITING |
| NCT04143724 | Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia | Phase II | RECRUITING |
| NCT06646276 | A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus | Phase III | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Bristol Myers Squibb Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.